指南与共识泌尿生殖技术与安全PETCT

晚期前列腺癌患者下一代影像学检查的临床医生指南(RADAR III)

A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III).
指南 / 共识 · J Urol · 2019-01-01

RADAR III专家组基于现有数据与临床经验,就下一代影像学在前列腺癌分期中的使用给出指导,认为进展为转移性疾病是患者治疗的关键事件,下一代影像能检出既往无法检出的转移灶,可能重新定义前列腺癌进展阶段。

要点

  • 基于实验室(生物标志物)值、合并症和症状怀疑疾病进展的选择性患者,推荐使用下一代影像技术。
  • 目前18F-氟环丁烷和68Ga前列腺特异性膜抗原PET/CT是兼具可得性、特异度和敏感度优势的下一代影像剂。
  • 下一代影像可检出既往无法检出的转移灶,可能重新定义前列腺癌进展阶段。

核心结论

  • 进展为转移性疾病是患者治疗的关键事件;下一代影像技术能检出既往无法检出的转移灶,可能重新定义前列腺癌进展阶段,早期全身或局部定向治疗可能积极改变患者结局。

研究设计与样本

  • RADAR III专家组基于现有数据和临床经验提供指导,就下一代影像用于前列腺癌分期的使用给出意见,并讨论下一代影像基于更早发现疾病对治疗选择的潜在影响。

诊断标准与关键数值

  • 基于实验室(生物标志物)值、合并症和症状怀疑疾病进展的选择性患者推荐使用下一代影像技术;目前18F-氟环丁烷和68Ga前列腺特异性膜抗原PET/CT是兼具可得性、特异度和敏感度优势的下一代影像剂。

临床应用与阅片要点

  • RADAR III专家组推荐在基于实验室(生物标志物)值、合并症和症状怀疑疾病进展的选择性患者中使用下一代影像技术;目前18F-氟环丁烷和68Ga前列腺特异性膜抗原PET/CT是兼具可得性、特异度和敏感度优势的下一代影像剂;其他下一代影像技术正在研究中,可能提供更好的诊断准确性和治疗选择。

局限性

  • 原文提及常在缺乏相关治疗数据的情况下基于最佳可用信息和当前临床经验提供指导。
  • 原文提及其他下一代影像技术正在研究中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The advanced prostate cancer therapeutic landscape has changed dramatically in the last several years, resulting in improved overall survival of patients with castration naïve and castration resistant disease. The evolution and development of novel next generation imaging techniques will affect diagnostic and therapeutic decision making. Clinicians must navigate when and which next generation imaging techniques to use and how to adjust treatment strategies based on the results, often in the absence of correlative therapeutic data. Therefore, guidance is needed based on best available information and current clinical experience.

MATERIALS AND METHODS: The RADAR (Radiographic Assessments for Detection of Advanced Recurrence) III Group convened to offer guidance on the use of next generation imaging to stage prostate cancer based on available data and clinical experience. The group also discussed the potential impact of next generation imaging on treatment options based on earlier detection of disease.

RESULTS: The group unanimously agreed that progression to metastatic disease is a seminal event for patient treatment. Next generation imaging techniques are able to detect previously undetectable metastases, which could redefine the phases of prostate cancer progression. Thus, earlier systemic or locally directed treatment may positively alter patient outcomes.

CONCLUSIONS: The RADAR III Group recommends next generation imaging techniques in select patients in whom disease progression is suspected based on laboratory (biomarker) values, comorbidities and symptoms. Currently 18F-fluciclovine and 68Ga prostate specific membrane antigen positron emission tomography/computerized tomography are the next generation imaging agents with a favorable combination of availability, specificity and sensitivity. There is ongoing research of additional next generation imaging technologies, which may offer improved diagnostic accuracy and therapeutic options. As next generation imaging techniques evolve and presumably result in improved global accessibility, clinician ability to detect micrometastases may be enhanced for decision making and patient outcomes.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Crawford ED, Koo PJ, Shore N, et al. A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). J Urol. 2019. PMID: 30077557. doi:10.1016/j.juro.2018.05.164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。